Cubist Systematic Strategies, LLC Zentalis Pharmaceuticals, Inc. Transaction History

Cubist Systematic Strategies, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$20.23 - $31.73 $1.47 Million - $2.31 Million	72,768 New	72,768 $1.58 Million
Q2 2022 Aug 15, 2022	SELL	$17.91 - $52.25 $142,527 - $415,805	-7,958 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$41.58 - $80.89 $330,893 - $643,722	7,958 New	7,958 $367,000
Q4 2021 Feb 14, 2022	SELL	$66.92 - $84.79 $466,298 - $590,816	-6,968 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$46.83 - $73.5 $306,783 - $481,498	6,551 Added 1570.98%	6,968 $464,000
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $15,599 - $25,958	417 New	417 $22,000
Q1 2021 May 17, 2021	SELL	$35.69 - $52.72 $187,515 - $276,990	-5,254 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$31.71 - $57.97 $166,604 - $304,574	5,254 New	5,254 $273,000

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.